In 2018, Temptime Corporation expanded the range and flexibility of the company’s vaccine vial monitors (VVMs), which monitor the temperature exposure of vaccines to ensure that they have not been compromised by excessive heat.
The World Health Organization (WHO) identified new parameters for the available sensitivities of VVMs based on the evolving programmatic needs of its global immunisation programme. For the first time in almost 20 years, new VVM types have been developed and are currently being qualified to address these new parameters.
Temptime expanded the VVM technology to address an increasing range of temperatures and shelf lives for new vaccines coming to market. Following three years of research and development (R&D), Temptime’s scientists created the first VVM to monitor vaccines and other pharmaceutical products stored at room temperature.
The company also added a new type of VVM with more specificity for monitoring refrigerated medications.
At the time, president and CEO of Temptime Renaat Van den Hooff said: “It is an honour to support the world’s leading health organisations in the delivery of new and critical medical products to people around the world.
“Our company is built on innovation and this technology is another contribution toward our mission of creating new solutions that will meaningfully improve global health.”
Founded in 1987, Temptime developed the first technology to monitor temperature exposure of vials containing the oral polio vaccine. Since then, the company has developed different temperature sensitivities of VVMs and grown to support the world’s leading health organisations and pharmaceutical companies with safely storing and distributing a range of vaccines and medical products worldwide.